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Epidemiological studies have suggested an inverse correlation between red wine consumption and the incidence of CVD. However, Champagne
wine has not been fully investigated for its cardioprotective potential. In order to assess whether acute and moderate Champagne wine consumption
is capable of modulating vascular function, we performed a randomised, placebo-controlled, cross-over intervention trial. We show that consump-
tion of Champagne wine, but not a control matched for alcohol, carbohydrate and fruit-derived acid content, induced an acute change in endo-
thelium-independent vasodilatation at 4 and 8 h post-consumption. Although both Champagne wine and the control also induced an increase in
endothelium-dependent vascular reactivity at 4 h, there was no significant difference between the vascular effects induced by Champagne or
the control at any time point. These effects were accompanied by an acute decrease in the concentration of matrix metalloproteinase (MMP-9),
a significant decrease in plasma levels of oxidising species and an increase in urinary excretion of a number of phenolic metabolites. In particular,
the mean total excretion of hippuric acid, protocatechuic acid and isoferulic acid were all significantly greater following the Champagne wine
intervention compared with the control intervention. Our data suggest that a daily moderate consumption of Champagne wine may improve vascular
performance via the delivery of phenolic constituents capable of improving NO bioavailability and reducing matrix metalloproteinase activity.
Champagne wine intake: Endothelial-independent vascular function: Matrix metalloproteinase-9 activity: Cardiovascular disease
Epidemiological studies have suggested that there is an
inverse correlation between the consumption of polyphenol-
rich foods and the prevention of CVD(1,2). Moderate red
wine intake has also been associated with a reduced coronary
artery disease mortality(3,4), which may be due to its ability to
improve endothelial function(5), induce an acute increase in
endothelium-dependent flow-mediated dilatation(6,7) and inhi-
bit endothelin-1 synthesis(8,9). These effects of red wine
have been linked to both its alcohol content and to its high
content of polyphenols, in particular flavonoids, hydroxycin-
namates and phenolic acids(10). Following consumption, nano-
molar quantities of flavonoids and other polyphenols enter the
circulation(10,11) where they may act to improve NO bioavail-
ability and/or inhibit endothelin-1(12,13). In support of this,
white wine, which has significantly lower concentration of
polyphenols, induces significant reduced vascular effects(14,15),
although its cardioprotective effects have been reported(16,17).
In contrast to white wine, Champagne wine is relatively
rich in polyphenols such as hydroxybenzoic acids,
hydroxycinnamic acids (and their tartaric derivative esters),
flavonoids, phenolic alcohols and phenolic aldehydes(18).
The increased levels of phenolics in Champagne wine derive
predominantly from the two red grapes, Pinot Noir and
Pinot Meunier, which are used in its production along with
the white grape Chardonnay(19). Moderate Champagne wine
consumption has been shown to exert a number of effects
in vivo, effecting peripheral serotonin and dopamine release(20)
and increasing plasma vitamin A concentration(21). Champagne
wine polyphenols have also be shown to protect cells against
injury induced by peroxynitrite(22), a physiologically relevant
oxidising species which has been implicated in vascular wall
pathology(23,24). However, thus far, there have been no studies
investigating its consumption and changes in endothelial
function and thus cardiovascular risk.
In the present study, we have performed a randomised,
single-blind, controlled, cross-over design study in order to
assess whether acute, moderate Champagne wine consumption
is capable of modulating endothelial function in healthy
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human volunteers. We show that consumption of Champagne
wine induces acute changes in endothelium-independent vaso-
dilatation but not endothelium-dependent vasodilatation.
These effects were accompanied by a change in the level of
matrix metalloproteinase-9 (MMP-9), reductions in plasma
levels of oxidants and with an increased urinary excretion of
a number of phenolic metabolites. Together, our data suggest
that moderate Champagne wine consumption may help to
improve cardiovascular risk via its effects on the vasculature
and that that these effects may be mediated by circulating
Champagne wine-derived polyphenols.
Material and methods
Materials
Phenolic standards (caffeic acid, ferulic acid, homovanillyl
alcohol, gallic acid, vanillic acid, p-hydrobenzoic acid, (þ)-
catechin, (2 )-epicatechin, hydroxytyrosol, vanillin, hydroxy-
hippuric acid, p-coumaric acid, protocatechuic acid, sinapic
acid, hydroferulic acid, 3,4-dihydroxyphenylacetic acid,
tryptophol, resveratrol, quercetin, hippuric acid) and type
H-1 b-glucuronidase from Helix pomatia (EC 3.2.1.31) were
all obtained from Sigma (Poole, Dorset, UK). Caftaric acid
was obtained from Apin Chemicals (Abingdon, Oxon, UK),
homovanillic acid was obtained from Lancaster Synthesis
Ltd (Heysham, Lancs, UK) and tyrosol and isoferulic acid
were purchased from Extrasynthese (Lyon, France). Solvents
were all of HPLC grade and were purchased from Fisher
Scientific (Loughborough, Leics, UK). Ethyl acetate was
purified by distillation on a Raschig column before use.
The K2EDTA, serum separation tubes and heparin vacutainer
tubes were obtained from BD Vacutainer (Oxford, Oxon, UK).
Wallace Y-can cannulas were from 3S Healthcare (Enfield,
London, UK).
Subjects
Healthy male and female subjects (n 15), aged between 20 and
65 years (mean age 39·5 (SEM 4·3) years) with a BMI of 18·9–
28·4 kg/m2 (mean BMI 23·6 (SEM 0·7) kg/m2), were recruited
from the University of Reading and surrounding area. Individ-
uals with diabetes mellitus, any form of liver or gastrointesti-
nal disorder, high blood pressure (.150/90 mm/Hg), anaemia,
gall bladder problems, present illness, or those taking dietary
supplements, consuming caffeine or aspirin, vigorous exercise
(more than three times £ 20 min per week), or alcohol
consumption more than 120 g (women) and 168 g (men) per
week were excluded from the study, along with pregnant or
lactating females. Subjects were healthy, based on a medical
questionnaire, and had normal concentrations of liver enzymes
(aspartate aminotransferase, alanine aminotransferase and
g-glutamyl transferase), normal Hb, packed cell volume and
leucocyte counts and an absence of glucose and protein in urine.
Study design
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures invol-
ving human subjects were approved by the University of
Reading Research Ethics Committee (ref. 07/16). The study
was also registered with the National Institutes of Health
(NIH) randomised trial records held on the NIH Clinical-
Trials.gov website (ref. NCT00937313) and with the Current
Controlled Trials website (ref. ISRCTN38867650). Written
informed consent was obtained from all subjects before the
study started. Subjects refrained from consuming high-poly-
phenol foods for 48 h before the start of the study and for
32 h post-initiation. In particular, the following foods and
beverages were excluded from volunteer diets: cocoa-contain-
ing products, coffee, tea and wine. The study was designed as
a single-blind, randomised, cross-over intervention trial, where
volunteers were asked to consume either 375 ml of Cham-
pagne wine (Chardonnay, Pinot Noir and Pinot Meunier;
12 % alcohol) or a control matched for alcohol content, fruit
sugars and acids (Table 1). The Champagne wine used in
the study contained no vitamin C. Subjects were assessed
for anthropometric measurements and provided a urine
sample before baseline laser Doppler imaging with iontophor-
esis (LDI) measurements (detailed below). Subjects were then
cannulated in the antecubital vein and one baseline blood
sample was collected. Subjects were then randomly assigned
to either the Champagne wine or control group and asked to
consume the beverage within a 10 min period. Following a
standardised breakfast, blood samples were collected at 15,
30, 45, 60, 120, 180, 240, 300, 360 and 480 min post-
consumption and pooled urine samples were collected over
3 £ 8 h periods. A standardised breakfast and lunch were
consumed at 15 and 200 min post-beverage. LDI measure-
ments were carried out at 120, 240, 360 and 480 min.
Subjects also provided 24 h and 32 h blood and urine samples.
Table 1. Composition of Champagne wine and placebo
(Mean values and standard deviations)
Mean SD
Concentration of phenolic constituents of Champagne (mg/l)*
Gallic acid 0·74 0·01
Protocatechuic acid 0·40 0·03
p-Hydrobenzoic acid 0·05 0·003
Caftaric acid 17·69 0·28
Tyrosol 20·12 0·75
(þ)-Catechin 2·68 0·05
Coutaric acid† 1·77 0·03
Caffeic acid 7·65 0·02
(–)-Epicatechin 1·63 0·08
Fertaric acid† 0·70 0·10
Ethyl gallate 3·36 0·05
p-Coumaric acid 2·67 0·02
Ferulic acid 0·69 0·01
Tryptophol 0·89 0·06
Resveratrol 0·11 0·08
Ethyl caffeate† 0·38 0·02
Ethyl coumarate† 0·1 0·02
Concentration of components common to Champagne and placebo
Glycerol (g/l) 5·70
Fructose (g/l) 3·00
Glucose (g/l) 2·70
Tartaric acid (g/l) 2·00
Lactic acid (g/l) 3·00
Citric acid (g/l) 0·04
Ethanol (mg/l) 120·00
* Calculated from three independent injections.
† Calculated using the equivalent of the corresponding cinnamic acid derivative.
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Following a washout period of 28 d, volunteers returned to
the unit to complete the second arm of the study where the
procedure above was repeated.
Laser Doppler imaging with iontophoresis
In all cases, subjects were rested in the supine position for
30 min in a temperature-controlled environment (22–248C)
before LDI determination. Peripheral microvascular function
was assessed using a validated technique which quantifies
the vasodilator responses to 1 % acetylcholine (endothelium-
dependent vasodilatation) and 1 % sodium nitroprusside
(endothelial-independent vasodilatation), delivered transder-
mally using iontophoresis. This non-invasive in vivo method
provides a robust surrogate marker of vascular function, as
described previously(25,26). For the vascular reactivity
measurements, participants were requested to lie in a semi-
recumbent position with their right arm supported. A tempera-
ture probe and iontophoresis chambers were attached to the
volar aspect of the forearm and freshly prepared solutions of
acetylcholine chloride (2·5 ml; 1 % (w/v) in 0·5 % (w/v)
NaCl solution; Sigma Aldrich, Poole, Dorset, UK) and
sodium nitroprusside (2·5 ml; 1 % (w/v) in 0·5 % (w/v) NaCl
solution; Sigma Aldrich) were introduced into the anodal
and cathodal chambers respectively. Following a basal
measurement of skin perfusion, an incremental current was
delivered progressively in 5mA steps (5, 10, 15 and 20mA)
to yield a total charge (current £ time) of 8000 coulombs
during a 20 min measurement. A series of fifteen scans was
performed as the current increased from 0 to 20mA (with a
further five scans performed following current termination)
and skin perfusion, or erythrocyte flux, was measured using
a laser Doppler imager (Moor Instruments Ltd, Axminster,
Devon, UK). In all cases the within-day and between-day
CV were less than 10 %, as previously reported(27).
Matrix metalloproteinase and tissue inhibitor of
metalloproteinase analysis
MMP and tissue inhibitor of metalloproteinase (TIMP) were
analysed by gelatine zymography and reverse zymography,
respectively, as previously described(28). Briefly, for the detec-
tion of gelatinases in serum, SDS-PAGE was performed on
gels containing 0·1 % gelatine and 9 % polyacrylamide.
Samples (dilution 1/50), previously mixed with loading
buffer (2 % SDS and 0·1 % bromophenol blue), were electro-
phoresed under non-reducing conditions. After electrophor-
esis, gels were washed in 2 % Triton X-100 and immersed
in buffer containing 50 mM-2-amino-2-hydroxymethyl-
propane-1,3-diol (Tris)-HCl (pH 7·6), 200 mM-NaCl and
10 mM-CaCl2 for 18 h at 378C. The gels were stained with
0·5 % Coomassie blue G-250 in acetic acid–methanol–water
(1:4:5, by vol.) and de-stained in acetic acid–methanol–
water (1:2:7, by vol.). The gelatinolytic activities appeared
as clear bands against the blue background of gelatine. For
the detection of TIMP in serum, SDS-PAGE was performed
on gels containing 0·1 % gelatine, 12 % polyacrylamide and
pro-MMP-2 (20 ng/ml). Samples (dilution 1/50), previously
mixed with loading buffer (2 % SDS and 0·1 % bromophenol
blue), were electrophoresed under non-reducing conditions.
After electrophoresis, gels were washed in 2 % Triton X-100
and immersed in buffer containing 50 mM-Tris-HCl (pH
7·6), 200 mM-NaCl and 10 mM-CaCl2 for 18 h at 378C.
The gels were stained with 0·5 % Coomassie blue G-250 in
acetic acid–methanol–water (1:4:5, by vol.) and de-stained
in acetic acid–methanol–water (1:2:7, by vol.). Reverse
zymography revealed inhibitory activity, which appeared as
blue zones against a clear background, demonstrating inhi-
bition of gelatine lysis in the gels. MMP-2, MMP-9, TIMP-1
and TIMP-2 concentrations in serum were quantified with
human commercial ELISA kits (Amersham Biosciences)
following the manufacturer’s instructions. Each sample was
assayed in duplicate, and the values were within the linear
portion of the standard curve.
HPLC analyses
Analysis of Champagne wine extracts for phenolic content
were performed as previously described(22). Determination of
the excreted urinary metabolites was carried out as follows:
untreated urine samples were filtered through a 0·45mm mem-
brane before HPLC analysis. For b-glucuronidase treatment,
urine samples (1 ml) were acidified with 1·2 M-acetic acid
(50ml) and mixed with b-glucuronidase (230 mg/ml in
0·2 M-sodium acetate; pH 5) under Ar for 45 min at 378C.
After addition of 1 M-HCl (40ml), samples were extracted
twice with ethyl acetate and centrifuged for 15 min at
5000 g. The combined organic layers were evaporated under
N2, re-dissolved by vortexing in 25 % aqueous methanol
(200ml), filtered (polytetrafluoroethylene (PTFE) membrane,
0·45mm; Millipore, Chandlers Ford, Hants, UK) and injected
(50ml) onto an Agilent 1100 Series HPLC linked to a diode
array detector. Sample separation was achieved using a C18
Nova Pakw column (250 £ 4·6 mm internal diameter; 5mm
particle size), fitted with a guard column C18 NovaPakw
(Waters Ltd, Elstree, Herts, UK). The mobile phase consisted
of: A, aqueous methanol (5 %) þ 5 M-HCl (0·1 %) and B,
acetonitrile–methanol (1:1) þ 5 M-HCl (0·1 %) and was
pumped through the column at 0·7 ml/min. Samples (50ml)
were injected and separated using the following gradient
system (min/% B): 0/5, 5/5, 40/50, 55/100, 59·9/100, 60/5
and the eluant was monitored by photodiode array detection
at 254, 280, 320 and 370 nm, with spectra of products obtained
over the 220–600 nm range. All data were analysed using
ChemStationw software (Agilent Technologies, Inc., Santa
Clara, CA, USA). Components were identified according
to retention time, UV or visible spectra and spiking with
commercially relevant standards when available.
Biochemical analysis
The blood samples collected in lithium–heparin tubes were
spun (1700 g; 10 min; 48C) immediately after collection.
Samples were also collected in serum separation tubes (SST)
and allowed to stand for 30 min before centrifugation
(1300 g; 10 min; 218C). All samples were sampled and
frozen at 2808C until analysis. All biochemical parameters
were assayed on an ILAB 600 chemistry analyser (Instrumen-
tation Laboratory, Warrington, Cheshire, UK) using enzyme-
based colorimetric tests supplied by Instrumentation Labora-
tory. The following parameters were determined in all
samples: total cholesterol, LDL-cholesterol, HDL-cholesterol,
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glucose, TAG, uric acid, total bilirubin, albumin, C-reactive
protein, aspartate aminotransferase, alanine aminotransferase
and g-glutamyl transferase. Plasma total antioxidant capacity
(TAC) was measured by using the TAC kit provided by Med-
icon SA (Gerakas, Greece) as reported previously(29). This
assay is based on the competition of a parallel reaction,
where the peroxyl-radical donor 2,2-azobis-(2-amidinopro-
pane) dihydrochloride (ABAP) bleaches the carotenoid
crocin. Antioxidants present in the sample then inhibit the
bleaching by trapping formed radicals. The assay was per-
formed at 378C in the following steps: 2ml of sample, calibra-
tor or control were mixed with 250ml of crocin reagent (R1)
and incubated for 160 s. Subsequently, 125ml ABAP (R2)
were added and the decrease in absorbance at 450 nm was
measured 256 s later. Values of TAC were expressed as
mmol/l of Trolox and corrected TAC values were calculated
from TAC after subtraction of the interactions due to endogen-
ous uric acid, bilirubin and albumin accounting for 0·11, 0·11
and 0·01 mmol/mg of the antioxidant capacity, respect-
ively(29,30). Endothelin-1 was determined using ELISA kits
obtained from R&D Systems (Abingdon, Oxon, UK). Total
NO levels were assessed by using the Total NO/Nitrite/Nitrate
assay kit (ref. KGE001) obtained from R&D Systems. Total
NO (NO2
2/NO3
2) in serum/plasma ranged between 10 and
97mmol/l (mean 37mmol/l; n 25). Before analysis, samples
were deproteinised by using 10 000 Da molecular-weight cut-
off filters (R&D Systems). Total oxidative capacity (TOC)
was determined by a rapid enzymic in vitro diagnostic assay
(POX-ACT) obtained from Tatzber KEG (Ho¨flein at the
Danube, Austria)(31). This assay measures endogenous levels
of peroxides, an indicator of either the production of pro-
oxidative substances by the organism or an impaired uptake
or consumption of antioxidants, using tetramethylbenzidine
as the chromogen substrate. This assay is robust and provides
intra- and inter-assay CV of 3·73 and 5·51 %, respectively.
Statistical analysis
Data were analysed using SPSS version 12.1 (SPSS, Inc.,
Chicago, IL, USA). Results are presented in the text and
figures as mean values with their standard errors. Bonferroni
tests for multiple comparisons and t tests were subsequently
used to examine differences between individual treatments.
All data were checked for normality and log-transformed
where necessary before statistical analysis. Values of
P,0·05 were taken as significant.
Results
Assessment of vascular reactivity by laser Doppler imaging
with iontophoresis
Consumption of both the Champagne wine (P¼0·030) and
the control (P¼0·045) induced an increase in endothelium-
dependent vascular reactivity at 4 h, as indicated by increases
in skin erythrocyte flux in the presence of acetylcholine chlor-
ide (Fig. 1(a)). These increases in vascular reactivity returned
to baseline by 8 h and there was no significant difference
between the vascular effects induced by Champagne wine or
the control at any time point. Endothelium-independent
vasodilatation (skin erythrocyte flux following iontophoresis
with sodium nitroprusside) was found to be significantly
increased at 4 and 8 h Champagne wine consumption
(P¼0·045 and P¼0·037, respectively) and a close to linear
correlation was found between treatment and time
(P¼0·057). In contrast, the alcohol-matched control did
not induce endothelium-independent changes in vascular
reactivity. Furthermore, there was a significantly greater
degree of endothelium-independent vasodilatation observed
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Fig. 1. Response of forearm skin erythrocyte flux v. baseline, following the
iontophoresis of (a) acetylcholine or (b) sodium nitroprusside. (–B–), Cham-
pagne; (- -X- -), placebo. Values are means, with standard errors represented
by vertical lines. The vasodilatation to sodium nitroprusside was significantly
higher in the Champagne wine group than the placebo group (P,0·05).
* Mean value was significantly different from that at baseline (0 h)
(P,0·05). † Mean value was significantly different from that following placebo
intake (P,0·05).
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Fig. 2. Variation of the concentration of the urinary metabolites assessed by HPLC after Champagne wine (–B–) or placebo (- -X- -) consumption: (a) hippuric
acid; (b) protocatechuic acid; (c) isoferulic acid; (d) homovanillic acid; (e) homovanillyl alcohol; (f) 3,4-dihydroxyphenylacetic acid (DOPAC). Values are means,
with standard errors represented by vertical lines. † Mean value was significantly different from that following placebo intake (P,0·05).
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Table 2. Time course of biochemical parameters after either Champagne wine or placebo intake
(Mean values with their standard errors)
Champagne Placebo
0 h 2 h 4 h 6 h 8 h 0 h 2 h 4 h 6 h 8 h
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Total cholesterol
(mmol/l)
4·99 1·04 4·89 0·96 4·88 1·01 4·81 0·96 4·89 0·99 4·96 1·02 4·88 0·89 4·98 0·88 5·02 0·87 5·15 0·91
HDL-cholesterol
(mmol/l)
1·60 0·45 1·53 0·42 1·53 0·50 1·44 0·38 1·50 0·50 1·67 0·50 1·65 0·47 1·62 0·48 1·55 0·46 1·65 0·51
LDL-cholesterol
(mmol/l)
3·16 0·92 3·09 0·90 3·00 0·84 2·80 0·76 3·04 0·85 3·04 0·90 2·98 0·83 2·68 1·06 2·96 0·84 3·11 0·88
TAG (mmol/l) 1·12 0·43 1·34 0·36 1·86 0·49 2·63*** 0·78 1·64 0·67 1·18 0·48 1·35 0·58 1·92 0·71 2·50*** 0·92 1·87 1·00
Glucose (mmol/l) 5·40 0·67 4·93 1·10 5·73 1·08 5·74 1·14 5·64 0·53 5·22 0·48 5·14 1·08 5·64 1·21 5·81 0·90 5·63 0·54
Albumin (g/l) 47·4 5·40 44·9 2·00 46·7 3·00 45·9 2·80 48·0 3·10 46·3 1·64 45·8 2·40 46·2 3·70 45·9 2·11 47·2 2·01
Total bilirubin
(mg/l)
101·0 49·1 78·5 32·4 74·6 32·3 65·5 26·9 61·9 25·7 105 42·6 92·0 28·8 60·0* 37·2 67·1 20·2 60·8* 27·7
Uric acid (mmol/l) 324 76·00 348 71·02 344 85·05 322 79·32 324 98·08 341 40·03 381 50·12 313 130·01 331 58·09 319 58·12
gGT (U/l) 22·6 11·80 20·9 12·30 21·3 10·90 19·5 10·50 22·5 10·90 21·6 9·50 21·1 9·60 18·7 10·50 20·7 10·60 21·4 11·00
AST (U/l) 21·3 6·32 20·4 4·13 20·2 4·49 24·1 7·15 22·1 4·60 23·5 8·84 22·9 8·88 23·4 10·0 23·0 7·95 24·5 8·86
ALT (U/l) 17·8 7·17 16·5 7·21 17·3 6·81 18·3 9·60 19·1 9·95 19·2 8·3 18·5 8·42 18·3 10·0 18·9 6·09 19·0 6·17
CRP ultra
sensitive (mg/l)
1·03 0·82 1·02 0·73 0·96 0·80 1·12 0·34 1·14 0·41 1·03 0·53 1·01 0·56 0·96 0·53 1·12 0·62 1·12 0·66
cTAC (mmol/l) 0·53 0·07 0·47 0·04 0·44 0·08 0·44 0·06 0·54 0·07 0·53 0·05 0·50 0·05 0·44 0·13 0·51 0·06 0·52 0·05
Total NO
(NO2
2/NO3
2)
(mmol/l)
24·9 0·40 25·5 0·60 24·4 0·90 24·8 0·80 24·6 0·40 24·9 0·40 26·1 0·60 24·1 0·40 24·1 0·40 24·8 0·50
Endothelin-1
(pg/ml)
0·73 0·04 0·67 0·04 0·69 0·03 0·77 0·04 0·75 0·03 0·73 0·05 0·68 0·04 0·76 0·05 0·76 0·04 0·78 0·04
gGT, g-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase, CRP, C-reactive protein, cTAC, corrected total antioxidant capacity.
Mean value was significantly different from that at baseline (0 h): * P,0·05, *** P,0·001.
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following Champagne wine intervention relative to placebo
intervention at 4, 6 and 8 h (P¼0·013, P¼0·034 and
P¼0·031, respectively).
Urinary excretion of polyphenols
The major phenolic derivatives indentified in urine were hip-
puric acid, protocatechuic acid, isoferulic acid, homovanillic
acid, homovanillyl alcohol and 3,4-dihydroxyphenylacetic
acid (Fig. 2). All of these compounds were present in baseline
urine samples and all, with the exception of isoferulic acid,
increased significantly over time following intervention with
either Champagne wine or the alcohol control (Fig. 2). How-
ever, the mean total excretion of hippuric acid (Champagne
wine, 159·30 (SEM 29·3) mg; control, 100·70 (SEM 20·8) mg;
P,0·001), protocatechuic acid (Champagne wine, 10·60
(SEM 1·30) mg; control, 7·17 (SEM 1·56) mg; P,0·05) and
isoferulic acid (Champagne wine, 2·04 (SEM 0·84) mg;
control, 0·24 (SEM 0·39) mg; P,0·001) were all significantly
greater following the Champagne wine intervention compared
with the control intervention. More specifically, hippuric acid
excretion (Fig. 2(a)) was significantly higher at 8 h (P¼0·032)
and 24 h (P¼0·036) and protocatechuic acid excretion
(Fig. 2(b)) was greater at 24 h (P¼0·038) post-Champagne
wine intervention compared with control. Isoferulic acid,
which was present at very low concentration in baseline
urine, increased significantly only following Champagne
wine consumption and was significantly different from control
at 24 h (P¼0·039) and 32 h (P¼0·011) post-intervention
(Fig. 2(c)). Although there was a tendency for excretion to
be increased following Champagne wine intervention, there
were no significant differences in the mean total excretion
of homovanillic acid (Champagne wine, 8·04 (SEM 1·51)
mg; control, 7·07 (SEM 1·73) mg), homovanillyl alcohol
(Champagne wine, 11·35 (SEM 1·91) mg; control, 9·15 (SEM
1·89)) or 3,4-dihydroxyphenylacetic acid (Champagne wine,
18·74 (SEM 3·58) mg; control, 21·34 (SEM 4·98) mg).
Biochemical markers
A significant increase in TAG concentrations was observed 6 h
post-consumption of both Champagne wine and control,
although there was no significant difference in the magnitude
of change induced by the two interventions (Table 2). No sig-
nificant changes in glucose, total cholesterol, HDL-cholesterol
or LDL-cholesterol were observed post-Champagne wine or
control consumption. All endothelial markers (endothelin-1,
total NOz/nitrite/nitrate) revealed values within a normal
healthy range but did not change significantly following
either intervention (Table 2). Liver enzyme levels (alanine
aminotransferase, aspartate aminotransferase, g-glutamyl
transferase) did not show any statistical changes in response
to either intervention. All biochemical markers were within
the expected healthy range.
Oxidative status and inflammatory markers
Intervention with both the control and Champagne wine led
to increases in ‘total oxidant capacity’ (TOC) over the 6 h
period immediately post-consumption, reflecting increases
in endogenous peroxide production (P,0·001; Fig. 3).
In general, this increase in TOC was greater following the
control intervention and was found to be significantly lower
in the Champagne wine group at 6 h post-intervention (11 %
reduction relative to placebo; P,0·01) (Fig. 3). In contrast,
there were no differences in ‘total antioxidant’ levels
(corrected TAC) following either intervention (Table 2).
Furthermore, there were no significant alterations in serum
levels of C-reactive protein following either intervention.
Matrix metalloproteinase and tissue inhibitor of
metalloproteinase levels
Gelatin–zymography analysis and ELISA revealed a stable
concentration of MMP-2 at 1, 6 and 23 h post-intervention
with Champagne wine and control (Fig. 4). In contrast,
MMP-9 significantly decreased 1 h post-Champagne wine con-
sumption (38·1 (SEM 6·3) %; P,0·05) but not following the
control intervention (Fig. 4(a) and (d)). No significant modifi-
cations in the concentrations of TIMP-1 and TIMP-2 were
observed (Fig. 4(b), (e) and (f)).
Discussion
Many epidemiological studies have suggested that a daily and
moderate consumption of red wine is associated with a lower
incidence of CVD(32 – 34). In agreement with this, previous
studies have indicated that red wine consumption significantly
improves enthothelial function(8) and that these effects can be,
in part, attributed to its polyphenol content(35). Many of
the effects of red wine are compatible with the action
of wine-derived polyphenols on endothelium-derived NOz
production, implying that NOz might be a mediator for their
vascular actions(36,37). Indeed, a rapid activation of endothelial
NO synthase and endothelium-dependent vasodilatation has
been reported for grape-derived polyphenols in vitro (38) and
a single dose of red wine has been shown to increase NOz
production(39) and endothelium-dependent dilation(40,41) in
healthy volunteers. There is also evidence that white wine
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Fig. 3. Variation of the total oxidative capacity over time after Champagne
wine (–B–) or placebo (- -X- -) consumption. Values are means, with stan-
dard errors represented by vertical lines. Champagne wine demonstrated a
significant decrease in the total oxidant capacity 6 h post-consumption when
compared with placebo. †† Mean value was significantly different from that
following placebo intake (P,0·01).
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and Cava (sparkling white wine) may exert vascular actions.
It has been suggested that such effects may result from
the synergistic actions of polyphenols and other phenolic
constituents on LDL oxidation and platelet function(42 – 44).
In the present study, we show that Champagne wine consump-
tion is capable of inducing acute vascular effects and in
modifying levels of specific vascular active components.
The consumption of either Champagne wine or the alcohol
control induced a rapid increase in endothelium-dependent
vasodilatation, which returned to basal levels after 8 h.
These observations are in agreement with previous studies
which indicate that moderate alcohol is capable of inducing
an acute increase in blood flow in an endothelium-dependent
manner(6,7,40,41,45). However, we found that only the
Champagne wine intervention was capable of significantly
inducing an increase in endothelium-independent vasodilata-
tion, which was maintained up to 8 h post-consumption.
These data suggest that moderate Champagne wine consump-
tion may enhance microvascular blood flow for a sustained
period, through maintenance of local NO levels, in this case
delivered via iontophoresis. Our data also suggest that this
effect may be mediated by absorbed Champagne wine poly-
phenols, the metabolites of which (hippuric acid, isoferulic
acid and protocatechuic acid) were detected in urine following
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Fig. 4. Evaluation of matrix metalloproteinase (MMP) (a) and tissue inhibitor of metalloproteinase (TIMP) (b) by gel zymography. (a) Gelatin zymogram showing
diminution of MMP-9 in blood 1 h after Champagne wine consumption. Human MMP-2 and MMP-9 were loaded as standards. (b) Reverse zymogram gel showing
no significant differences after Champagne wine or placebo consumption. Evaluation of (c) MMP-2, (d) MMP-9, (e) TIMP-1 and (f) TIMP-2 concentrations by
ELISA after Champagne wine ( ) or placebo (A) consumption. Samples were studied in duplicate. Data are expressed as percentage of control (baseline; 30 min
before Champagne wine or placebo intake). Values are means, with standard deviations represented by vertical lines. * Mean value was significantly different from
that at baseline (30 min before Champagne wine or placebo intake) (P,0·05).
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Champagne wine ingestion. These metabolites are known to
derive from the bacterial metabolism of caffeic acid
and other hydroxycinnamates in the large intestine(46).
Whilst urinary hippuric acid may derive from aromatic
amino acids, its increased excretion following Champagne
wine ingestion indicates that absorption and metabolism of
Champagne wine phenolic compounds, such as caffeic acid,
had occurred post-consumption(46). In support of this, the
increased excretion of isoferulic acid after Champagne wine
consumption is a specific biomarker of caffeic acid absorption,
as this metabolites is only derived from the 4-methoxylation of
caffeic acid by catechol-O-methyltransferase(47) before or
after its absorption(46). Furthermore, the majority of urinary
isoferulic acid has been shown to result from the cleavage
of the caffeoyl quinic acid derivative of caffeic acid(10,48).
Protocatechuic acid, which also increased in response to
Champagne wine intervention, has previously been detected
in human plasma following red wine consumption(49) and has
been identified as the urinary product of hydroxycinnamate
ingestion from various food sources(50,51).
The presence of such metabolites in urine between 6 and
32 h suggests that caffeic acid and other phenolic metabolites
are absorbed into the circulation following Champagne wine
consumption. These phenolic metabolites may affect vascular
function by improving local NO bioavailability by two
potential mechanisms. First, they may increase the local
half-life of NOz via reaction with reactive oxygen species,
such as superoxide(52 – 54). In support of this, we observed a
significant reduction in the ‘total oxidant capacity’ following
Champagne wine intake, indicating that Champagne wine
intervention leads to a reduction in plasma oxidant levels
relative to control. Second, phenolic metabolites, such as
those excreted post-Champagne wine consumption, may
mimic NADPH oxidase inhibitors(55 – 57), such as apocynin
(40-hydroxy-30-methoxyacetophenone), thereby reducing the
cellular production of superoxide and increasing the half-life
of NOz, without any change in the rate of NOz synthesis(56).
Indeed, previous studies have shown that the presence of an
aromatic vicinal hydroxy-methoxy arrangement is highly
effective in defining NADPH oxidase inhibition(56,57).
Champagne wine phenolics such as tyrosol, hydroxytyrosol,
ferulic acid and homovanillic alcohol have been shown to
outcompete apocynin with respect to its inhibitory potency(57).
The combined inhibition of NADPH oxidase and the
scavenging of reactive oxygen species by phenolic metabolites
would be expected to affect local NOz concentrations without
influencing global endothelial NO production. Such effects
may influence blood pressure, something which is supported
by previous data showing that a low-molecular-weight fraction
(1 kDa) of Champagne wine induces an anti-hypertensive
effect in animals(58). Another study investigating the effect
of olive oil phenolic components in rat aortic rings has
demonstrated that caffeic acid is able to induce a vasorelaxant
effect which persists in denuded aorta and in conjunction with
NO synthase inhibitors such as NG-methyl-L-arginine
(L-NMMA) or methylene blue(59). This suggests that the
vascular effects induced by this phenolic may be mediated
by the inhibition of Ca2+ channels and/or the blockage of
the protein kinase C-mediated contractile mechanism, as
has been observed for caffeic acid phenyl ester and sodium
ferulate, respectively(60,61). Further investigation is necessary
to unravel the precise mechanism by which Champagne
wine phenolics modulate endothelium-independent vasore-
laxation in vivo.
The Champagne wine intervention also had a potentially
beneficial effect on the vascular system in its ability to inhibit
MMP-9. MMP and their specific tissue inhibitors (TIMP) play
an important role in the physiological maintenance of the
extracellular matrix and the pathogenesis of vascular
disease(62,63). For example, the over-expression of MMP-9
has been reported in atherosclerotic plaques(64) and has been
linked with plaque rupture through its capacity to thin the
protecting fibrous cap of the plaque(65,66). Individual red
wine phenolics have been shown to inhibit gelatinase
expression and/or activity(67). A transient inhibition of
MMP-9 by Champagne wine phenolics could influence type
IV collagen degradation and therefore improve basement
membrane structural integrity. Although unlikely to have
long-term implications on the vascular system, this acute
inhibition of MMP-9 appears to be consistent with our other
observations, as the ability of Champagne wine phenolics to
reduce plasma oxidant formation would be expected to inhibit
peroxynitrite formation, an oxidant known to activate MMP-9.
Its effects on endothelial-independent vascular reactivity
may indicate that Champagne wine has the potential to
improve ‘reactivity’ in the cutaneous microvasculature (arter-
ioles, capillaries and venules). If so, it could reduce stiffening
of the conduit arteries and a decline in arterial compliance,
something which is observed with ageing, in hypertensive
patients, in diabetics and those with cardio- and cerebrovascu-
lar disease(68). Our findings may have wider significance in
that attenuated cutaneous microvascular responses in heart
transplant patients are paralleled by reduced responsiveness
of coronary blood vessels(69). As such, our data suggest that
moderate Champagne wine consumption may improve micro-
vasculature blood flow and therefore vascular responsiveness
generally. Further investigation will be necessary to determine
whether acute, or indeed chronic, intake of Champagne
has the potential to reduce CVD risk through its effects on
microvascular responsiveness.
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